Corcept Therapeutics/$CORT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Ticker
$CORT
Sector
Primary listing
Employees
730
Headquarters
Website
CORT Metrics
BasicAdvanced
$10bn
233.93
$0.40
0.36
-
Price and volume
Market cap
$10bn
Beta
0.36
52-week high
$94.77
52-week low
$28.66
Average daily volume
1m
Financial strength
Current ratio
2.856
Quick ratio
2.529
Long term debt to equity
1.256
Total debt to equity
1.511
Profitability
EBITDA (TTM)
-6.935
Gross margin (TTM)
98.25%
Net profit margin (TTM)
6.16%
Operating margin (TTM)
-1.07%
Effective tax rate (TTM)
-290.31%
Revenue per employee (TTM)
$1,050,000
Management effectiveness
Return on assets (TTM)
-0.62%
Return on equity (TTM)
7.17%
Valuation
Price to earnings (TTM)
233.926
Price to revenue (TTM)
12.71
Price to book
15.82
Price to tangible book (TTM)
15.82
Price to free cash flow (TTM)
81.359
Free cash flow yield (TTM)
1.23%
Free cash flow per share (TTM)
1.156
Growth
Revenue change (TTM)
12.20%
Earnings per share change (TTM)
-64.81%
3-year revenue growth (CAGR)
22.95%
10-year revenue growth (CAGR)
29.89%
3-year earnings per share growth (CAGR)
-20.83%
10-year earnings per share growth (CAGR)
39.20%
What the Analysts think about CORT
Analyst ratings (Buy, Hold, Sell) for Corcept Therapeutics stock.
CORT Financial Performance
Revenues and expenses
CORT Earnings Performance
Company profitability
CORT News
AllArticlesVideos
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
Business Wire·3 weeks ago
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
Newsfile Corp·3 weeks ago
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs